Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dow seeks return of old UK aminopyralid stocks

Dow AgroSciences has called on UK farmers to return old stocks of products containing its herbicide, aminopyralid. The UK Chemicals Regulation Directorate suspended the approval for sale, supply, and use of the active ingredient in 2008 ( Agrow No 549, p 14), but the suspension was lifted in October 2009 ( Agrow No 578, p 12). The company says that while aminopyralid has regained authorisation for use on grassland, any old stocks remaining on farm cannot be used as labels will not reflect the newly-approved use instructions. Dow’s aminopyralid-based product, Forefront, will be supplied with a new label under a new registration number. “Farmers will not be complying with the regulations governing correct use of crop protection products if they look to use any aminopyralid product – Forefront, Pharaoh or Banish – that was supplied before the products were suspended in 2008,” says a Dow technical specialist.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG001613

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel